Table 1 Independent factors for survival prediction multivariate analysis of patients

From: Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer

Variables

Characteristics

Univariate

P value

Multivariate

P value

  

HR (95% CI)

 

HR (95% CI)

 

SRCC status

Non-SRCC vs. Con-SRCC

1.16 (0.99–1.36)

0.06

1.16 (0.99–1.36)

0.06

 

Non-SRCC vs. SRCC

1.48 (1.25–1.75)

<0.001

1.45 (1.22 –1.71)

<0.001

Age (years)

<60 vs. ≥60

1.17 (1.02–1.34)

0.021

  

Gender

Male vs. Female

0.98 (0.84–1.13)

0.74

  

Tumor size (cm)

<5 vs. ≥5

2.62 (2.26–3.03)

<0.001

1.49 (1.27–1.75)

<0.001

Tumor location

Non-AEG vs. AEG

1.21 (1.04–1.40)

0.012

  

Tumor grade

G1–2 vs. G3-4

1.61 (1.34–1.94)

<0.001

  

Residual degree

R0 vs. R1/R2

2.98 (2.52–3.54)

<0.001

1.41 (1.17–1.71)

<0.001

T stage

T1–3 vs. T4

3.27 (2.77–3.86)

<0.001

  

N stage

N0 vs. N1-3

3.43 (2.84–4.14)

<0.001

  

M stage

M0 vs. M1

3.67 (3.09–4.36)

<0.001

  

TNM stage

I vs. II

2.00 (1.48–2.70)

<0.001

1.88 (1.38–2.55)

<0.001

 

I vs. III

5.08 (3.93–6.55)

<0.001

3.88 (2.96–5.10)

<0.001

 

I vs. IV

11.64 (8.74–15.51)

<0.001

7.58 (5.50 –10.42)

<0.001

Nervous invasion

Negative vs. Positive

1.62 (1.30–2.02)

<0.001

  

Capillary invasion

Negative vs. Positive

1.62 (1.39–1.88)

<0.001

1.20 (1.03–1.41)

0.019

Extranodal metastasis

Negative vs. Positive

2.50 (2.11–2.95)

<0.001

1.28 (1.07–1.52)

0.007

Chemotherapy

With vs. Without

1.25 (1.09-1.43)

0.002

1.46 (1.27–1.68)

<0.001

  1. P value and ORs were estimated by the Cox regression model
  2. HR Hazard ratio, 95% CI 95% confidence interval of the risk ratio, non-SRCC cancers without signet-ring cells, con-SRCC cancers with <50% presence of signet-ring cells, SRCC cancers with >50% presence of signet-ring cells, U upper, M middle, L lower, AEG adenocarcinomas of the esophagogastric junction